Are SGLT2 Inhibitors Reasonable Antihypertensive Drugs and Renoprotective?
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Are SGLT2 Inhibitors Reasonable Antihypertensive Drugs and Renoprotective?
Authors
Keywords
Sodium-glucose-linked cotransporter-2, Blood pressure, Diabetes mellitus, Tubuloglomerular Feedback, Diabetic nephropathy
Journal
CURRENT HYPERTENSION REPORTS
Volume 17, Issue 6, Pages -
Publisher
Springer Nature
Online
2015-04-17
DOI
10.1007/s11906-015-0551-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Empagliflozin, an SGLT2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
- (2015) John R. White ANNALS OF PHARMACOTHERAPY
- The impact of hyperfiltration on the diabetic kidney
- (2015) E. Premaratne et al. DIABETES & METABOLISM
- Blood Pressure Reduction: An Added Benefit of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes: Table 1
- (2015) Colleen Majewski et al. DIABETES CARE
- Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes
- (2015) B. Bode et al. DIABETES OBESITY & METABOLISM
- Treating Hypertension in Patients With Diabetes
- (2015) Bryan Williams JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Blood Pressure Lowering in Type 2 Diabetes
- (2015) Connor A. Emdin et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Possible adverse effects of SGLT2 inhibitors on bone
- (2015) Simeon I Taylor et al. Lancet Diabetes & Endocrinology
- Sodium/Glucose Cotransporter 2 Inhibitors and Prevention of Diabetic Nephropathy: Targeting the Renal Tubule in Diabetes
- (2014) Luca De Nicola et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Canagliflozin, a Novel SGLT2 Inhibitor for Treatment of Type 2 Diabetes
- (2014) Stefanie C. Nigro et al. ANNALS OF PHARMACOTHERAPY
- The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension
- (2014) Kaberi Dasgupta et al. CANADIAN JOURNAL OF CARDIOLOGY
- Sodium-Glucose Cotransporter 2 Inhibition in Type 1 Diabetes: Simultaneous Glucose Lowering and Renal Protection?
- (2014) David Z.I. Cherney et al. Canadian Journal of Diabetes
- The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
- (2014) David ZI Cherney et al. Cardiovascular Diabetology
- Adverse effects and safety of SGLT-2 inhibitors
- (2014) S. Halimi et al. DIABETES & METABOLISM
- SGLT-2 inhibition in patients with kidney disease
- (2014) R.E. Gilbert DIABETES & METABOLISM
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2014) Silvio E. Inzucchi et al. DIABETES CARE
- Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
- (2014) André J. Scheen DRUGS
- Effect of Canagliflozin on Blood Pressure and Adverse Events Related to Osmotic Diuresis and Reduced Intravascular Volume in Patients With Type 2 Diabetes Mellitus
- (2014) Matthew R. Weir et al. Journal of Clinical Hypertension
- Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis
- (2014) William L. Baker et al. Journal of the American Society of Hypertension
- Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors
- (2014) Raymond V. Oliva et al. Journal of the American Society of Hypertension
- The perils of clinical trials
- (2014) Richard E. Gilbert KIDNEY INTERNATIONAL
- Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice
- (2014) Naoto Terami et al. PLoS One
- Inhibition of Kidney Proximal Tubular Glucose Reabsorption Does Not Prevent against Diabetic Nephropathy in Type 1 Diabetic eNOS Knockout Mice
- (2014) Muralikrishna Gangadharan Komala et al. PLoS One
- Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
- (2014) Michael Nauck Drug Design Development and Therapy
- Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
- (2014) Anthony H Barnett et al. Lancet Diabetes & Endocrinology
- Renal effects of dapagliflozin in patients with type 2 diabetes
- (2014) Merlin C. Thomas Therapeutic Advances in Endocrinology and Metabolism
- Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes
- (2013) Despoina Vasilakou et al. ANNALS OF INTERNAL MEDICINE
- Type 2 Diabetes Mellitus Management in Canada: Is It Improving?
- (2013) Lawrence A. Leiter et al. Canadian Journal of Diabetes
- Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes
- (2013) R. A. DeFronzo et al. DIABETES CARE
- Standards of Medical Care in Diabetes--2014
- (2013) DIABETES CARE
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
- (2013) H. J. Lambers Heerspink et al. DIABETES OBESITY & METABOLISM
- 2013 ESH/ESC Guidelines for the management of arterial hypertension
- (2013) EUROPEAN HEART JOURNAL
- Ambulatory Blood Pressure Measurement
- (2013) Eoin O’Brien et al. HYPERTENSION
- 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults
- (2013) Paul A. James et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Kidney Disease and Increased Mortality Risk in Type 2 Diabetes
- (2013) M. Afkarian et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Sodium–glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?
- (2013) Richard E. Gilbert KIDNEY INTERNATIONAL
- Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
- (2013) Donald E. Kohan et al. KIDNEY INTERNATIONAL
- Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
- (2013) William T Cefalu et al. LANCET
- Dapagliflozin for the Treatment of Type 2 Diabetes
- (2012) Sarah L Anderson et al. ANNALS OF PHARMACOTHERAPY
- Hyperfiltration in type 1 diabetes: does it exist and does it matter for nephropathy?
- (2012) M. C. Thomas et al. DIABETOLOGIA
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat
- (2011) Scott C. Thomson et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials
- (2011) Giovanni Musso et al. ANNALS OF MEDICINE
- Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose
- (2011) Sripal Bangalore et al. CIRCULATION
- Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Renal Hyperfiltration and the Development of Microalbuminuria in Type 1 Diabetes
- (2009) L. H. Ficociello et al. DIABETES CARE
- Global estimates of the prevalence of diabetes for 2010 and 2030
- (2009) J.E. Shaw et al. DIABETES RESEARCH AND CLINICAL PRACTICE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started